Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Feb;42(2):563-578.
doi: 10.1007/s10067-022-06393-8. Epub 2022 Oct 6.

Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry

Carolina A Isnardi  1 , Karen Roberts  2 , Verónica Saurit  3 , Ingrid Petkovic  4 , Roberto M Báez  5 , Rosana Quintana  6 , Yohana Tissera  7 , Sofía Ornella  8 , Maria Eugenia D Angelo Exeni  9 , Cecilia N Pisoni  10 , Vanessa V Castro Coello  11 , Guillermo Berbotto  12 , María J Haye Salinas  13 , Edson Velozo  14 , Álvaro A Reyes Torres  15 , Romina Tanten  15 , Marcos D Zelaya  16 , Carla Gobbi  17 , Carla G Alonso  18 , María de Los Ángeles Severina  19 , Florencia Vivero  20 , Alba Paula  21 , Adriana K Cogo  22 , Gelsomina Alle  15 , Mariana Pera  23 , Romina E Nieto  24 , Micaela Cosatti  10 , Cecilia Asnal  25 , Dora Pereira  26 , Juan A Albiero  27 , Verónica G Savio  28 , Federico N Maldonado  11 , María Julieta Gamba  29 , Noelia F Germán  30 , Andrea Baños  31 , Josefina Gallino Yanzi  32 , María Soledad Gálvez Elkin  33 , Julieta S Morbiducci  34 , María Victoria Martire  35 , Hernán Maldonado Ficco  36 , Maria Marcela Schmid  32 , Jaime A Villafañe Torres  37 , Maria de Los Ángeles Correa  38 , María Alejandra Medina  39 , María Alejandra Cusa  40 , Julia Scafati  8 , Santiago E Agüero  41 , Nicolás M Lloves Schenone  42 , Enrique R Soriano  15 , Cesar Graf  43 , Bernardo A Pons-Estel  6 , Gimena Gomez  2 , Margarita Landi  2 , María Celina De la Vega  43 , Guillermo J Pons-Estel  2 ; S. A. R.–COVID Registry Investigators
Collaborators, Affiliations

Sociodemographic and clinical factors associated with poor COVID-19 outcomes in patients with rheumatic diseases: data from the SAR-COVID Registry

Carolina A Isnardi et al. Clin Rheumatol. 2023 Feb.

Abstract

Background/objective: This study aims to describe the course and to identify poor prognostic factors of SARS-CoV-2 infection in patients with rheumatic diseases.

Methods: Patients ≥ 18 years of age, with a rheumatic disease, who had confirmed SARS-CoV-2 infection were consecutively included by major rheumatology centers from Argentina, in the national, observational SAR-COVID registry between August 13, 2020 and July 31, 2021. Hospitalization, oxygen requirement, and death were considered poor COVID-19 outcomes.

Results: A total of 1915 patients were included. The most frequent rheumatic diseases were rheumatoid arthritis (42%) and systemic lupus erythematosus (16%). Comorbidities were reported in half of them (48%). Symptoms were reported by 95% of the patients, 28% were hospitalized, 8% were admitted to the intensive care unit (ICU), and 4% died due to COVID-19. During hospitalization, 9% required non-invasive mechanical ventilation (NIMV) or high flow oxygen devices and 17% invasive mechanical ventilation (IMV). In multivariate analysis models, using poor COVID-19 outcomes as dependent variables, older age, male gender, higher disease activity, treatment with glucocorticoids or rituximab, and the presence of at least one comorbidity and a greater number of them were associated with worse prognosis. In addition, patients with public health insurance and Mestizos were more likely to require hospitalization.

Conclusions: In addition to the known poor prognostic factors, in this cohort of patients with rheumatic diseases, high disease activity, and treatment with glucocorticoids and rituximab were associated with worse COVID-19 outcomes. Furthermore, patients with public health insurance and Mestizos were 44% and 39% more likely to be hospitalized, respectively.

Study registration: This study has been registered in ClinicalTrials.gov under the number NCT04568421. Key Points • High disease activity, and treatment with glucocorticoids and rituximab were associated with poor COVID-19 outcome in patients with rheumatic diseases. • Some socioeconomic factors related to social inequality, including non-Caucasian ethnicity and public health insurance, were associated with hospitalization due to COVID-19.

Keywords: Argentina; COVID-19; Rheumatic diseases; SARS-CoV-2.

PubMed Disclaimer

Conflict of interest statement

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: SAR-COVID is a multi-sponsor registry, where Pfizer, Abbvie, and Elea Phoenix provided unrestricted grants. None of them participated or influenced the development of the project, data collection, analysis, interpretation, or writing of the report. They do not have access to the information collected in the database.

Figures

Fig. 1
Fig. 1
COVID-19 symptoms most frequently reported in the SAR-COVID registry
Fig. 2
Fig. 2
Sociodemographic and clinical factors associated with A hospitalization, B severe oxygen requirements, and C death due to COVID-19. Only significant associations are shown. The models have been adjusted for the following variables: sex, age, ethnicity, socioeconomic level, health insurance, education, comorbidities, smoking status, rheumatic disease diagnostic, activity, and treatment. ref, reference; SS, social security; PH, private health; HDA, high disease activity; MDA, moderate disease activity; LDA, low disease activity; PDN, prednisone
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Furst DE. The risk of infections with biologic therapies for rheumatoid arthritis. Semin Arthritis Rheum. 2010;39:327–346. doi: 10.1016/j.semarthrit.2008.10.002. - DOI - PubMed
    1. Auyeung TW, Lee JS, Lai WK, et al. The use of glucocorticoids as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005;51:98–102. doi: 10.1016/j.jinf.2004.09.008. - DOI - PMC - PubMed
    1. Hui DS. Systemic corticoid therapy may delay viral clearance in patients with middle east respiratory syndrome coronavirus infection. Am J Respir Crit Care Med. 2018;197:700–701. doi: 10.1164/rccm.201712-2371ED. - DOI - PubMed
    1. Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists´ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020;39:2055–2062. doi: 10.1007/s10067-020-05073-9. - DOI - PMC - PubMed
    1. Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R. COVID-19 infection and rheumatoid arthritis: faraway, so close! Autoimmun Rev. 2020;19:102523. doi: 10.1016/j.autrev.2020.102523. - DOI - PMC - PubMed

Associated data